Jason C. Sniffen, D.O., F.A.C.O.I., F.A.C.P., F.I.D.S.A.
Dr. Sniffen has practiced infectious diseases in the Orlando area since 2001. He is the immediate past President of Infectious Disease Consultants, MD PA, one of the busiest infectious diseases practices in the United States.
After completing his fellowship training in infectious diseases at the University of South Florida, College of Medicine in Tampa, Florida, Dr. Sniffen relocated to Orlando. He continues as a Clinical Assistant Professor in the Department of Infectious Diseases at South Florida College of Medicine. Additionally, Dr. Sniffen teaches medical students, residents, and fellows from Advent Health System’s many training programs.
Dr. Sniffen is Board Certified in Infectious Diseases, Internal Medicine and Hyperbaric Medicine. He is the immediate past Chair of ID for the Advent Health System. Dr. Sniffen has served as Chief of Staff, Chief Medical Advisor, Chair of the Pharmacy and Therapeutics Committee within the system. He currently serves on the Physicians’ Health Advisory Committee and the Antibiotic Stewardship Committee for Advent Health System in Orlando.
Dr. Sniffen is a Fellow of the American College of Physicians, American College of Osteopathic internists and has earned the prestigious title of “Fellow of the Infectious Disease Society of America, (FIDSA).”
Dr. Sniffen has been repeatedly named to the “Finest Doctors in Orlando” by the Orlando Magazine. At the national level, Dr. Sniffen is past chairman of the American Osteopathic Board of Internal Medicine (AOBIM) and past chairman of the ID Section of the board, a position he held for 11 years and continues to serve as an adviser. Dr. Sniffen has dozens of publications to his credit in medical journals, textbooks, and online.
Dr. Sniffen has received multiple awards of excellence in medicine during his career and was a graduate of the Inaugural Physician Leadership Program at Advent Health System.
Maziade PJ, Ship N, Sniffen JC, Goldstein EJC. Clin Infect Dis. 2021 May 9: ciab414. doi: 10.1093/cid/ciab414. Online ahead of print. PMID: 33966076
Ballantyne E, Carr A, Ensor C, Sniffen J, Minor S, Lopez-Ruiz A, Subedi B, Louzon P, Wooten L. Interleukin-6 (IL-6) Receptor Antagonism with Tocilizumab for COVID-19 Related Cytokine Release Syndrome (CRS): Initial Outcomes.
Poster presented at MAD-ID 2021; May 2021; Virtual.
Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury Davide Ventura, Amy L Carr, R Duane Davis, Scott Silvestry, Linda Bogar, Nirav Raval, Cynthia Gries, Jillian E Hayes, Eduardo Oliveira, Jason Sniffen, Open Forum Infectious Diseases, ofab170, https://doi.org/10.1093/ofid/ofab170 Published: 04 April 2021
ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. Oliveira E, Parikh A, Lopez-Ruiz A, Carrilo M, Goldberg J, Cearras M, Fernainy K, Andersen S, Mercado L, Guan J, Zafar H, Louzon P, Carr A, Baloch N, Pratley R, Silverstry S, Hsu V, Sniffen J, Herrera V, Finkler N. PLoS One. 2021 Mar 25;16(3):e0249038. doi: 10.1371/journal.pone.0249038. eCollection 2021.PMID: 33765049
Choosing an appropriate probiotic product for your patient: An evidence-based practical guide. Sniffen JC, McFarland LV, Evans CT, Goldstein EJC. PLoS One. 2018 Dec 26;13(12):e0209205. doi: 10.1371/journal.pone.0209205. eCollection 2018.
Probiotics and prevention of Clostridium difficile infection